Application Notes

Cellastim S – Reconstitution Application Note

rHSA Reconstitution Video Protocol

Exbumin – Stabilizing Virus with Albumin to Improve Yield Application Note

Blog

Recombinant Albumin for Stabilization of Live-Attenuated Viral Vaccines

Recombinant Virus Platforms are Out in Front in the Race to Develop Vaccines Against SARS-CoV-2 and COVID-19 Disease

Solving the Vaccine Supply Challenge

Journal Articles (DOI Links)

Utilization of Recombinant Albumins in the Expansion of Human T Lymphocytes

Accurate nanoelectrode recording of human pluripotent cell-derived cardiomyocytes for assaying drugs and modeling disease

Posters

Exbumin®, an EMA and FDA approved excipient, provides improved performance and stability in vaccine development and final formulations

Virus Yield Improvement for Downstream Processing: Exbumin®, Excipient Recombinant Albumin

SDS

Exbumin – Safety Data Sheet

Optibumin – Safety Data Sheet

Cellastim S – Safety Data Sheet

Use Guidelines

Cellastim S – Guidelines for Use

Exbumin – Guidelines for Use

Webinar

Accelerating Vaccine Development Through Use of Blood-Free Components

White Papers

High-Quality Recombinant Human Serum Albumin (rHSA), Exbumin™, for Improved Cell Wash Buffer Preparation

Cellastim S – Recombinant Human Serum Albumin in the Generation of Functional Cardiomyocytes from Pluripotent Stem Cells

Emergence of Blood-Free Recombinant Human Albumin

Optimizing the Performance of LNP and Liposome Therapeutics with Blood-Free Recombinant Albumin